Measurement of ganciclovir concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry

Clinica Chimica Acta

Volumn 427, Issue , 2014, Pages 58-64

  Rigo Bonnin, Raül ^a   Padullés, Ariadna ^a   Corral Comesaña, Sofía ^a   Cerezo, Gema ^a   Grinyó, Josep Maria ^a   Colom, Helena ^b   Alía Ramos, Pedro ^a   Lloberas, Núria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acyclovir; Cytomegalovirus; Ganciclovir; Therapeutic drug monitoring; UPLC MS MS; Valganciclovir

Indexed keywords

ACICLOVIR; AMMONIUM ACETATE; FORMIC ACID; GANCICLOVIR; METHANOL; WATER;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETER; MEASUREMENT ACCURACY; PREDICTION; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GANCICLOVIR; HUMANS; TANDEM MASS SPECTROMETRY;

EID: 84886263236     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.09.049     Document Type: Article

References (35)

1. Tolkoff-Rubin N.E., Rubin R.H. The impact of cytomegalovirus infections on graft function and patient outcome. Graft 1999, S101-S103. [Suppl.].
2. McGavin J.K., Goal J.K. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61:1153-1183.
3. Crumpacker C.S. Ganciclovir. N Engl J Med 1996, 335:721-729.
4. Pescovitz M.D., Rabkin J., Merino R., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000, 44:2811-2815.
5. Pescovitz M.D., Pruett T.L., Gonwa T., et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998, 66:1104-1107.
6. Wiltshire H., Hirankarn S., Farrell C., et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir in solid organ transplant recipients. Clin Pharmacokinet 2005, 44:495-507.
7. Wiltshire H., Paya C., Pescovitz M.D., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005, 79:1477-1483.
8. Caldés A., Colom H., Armendariz Y., et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother 2009, 53:4816-4824.
9. Bedino G., Esposito P., Bosio F., et al. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int Urol Nephrol 2012, 10.1007/s11255-012-0293-y.
10. Piketty C., Bardin C., Gilquin J., et al. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 2000, 6:117-120.
11. Fishman J., Doran M., Volpicelli S., et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant. Transplantation 2000, 69:389-394.
12. Zhao W., Fakhoury M., Fila M., et al. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. Ther Drug Monit 2012, 34:326-330.
13. Padullés A., Colom H., Armendariz Y., et al. Determination of ganciclovir in human plasma by ultra performance liquid chromatography-UV detection. Clin Biochem 2012, 45:309-314.
14. Yoshida T., Takahashi R., Imai K., Uchida H., Arai Y., Oh-ishi T. A simple, sensitive determination of ganciclovir in infant plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr Sci 2010, 48:208-211.
15. Dao Y.J., Jiao Z., Zhong M.K. Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 867:270-276.
16. Asberg A., Nupen Hansen C., Reubsaet L. Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. J Pharm Biomed Anal 2007, 43:1039-1044.
17. Teshima D., Otsubo K., Yoshida T., Itoh Y., Oishi R. A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chormatography. Biomed Chromatogr 2003, 17:500-503.
18. Merodio M., Campanero M.A., Mirshahi T., Mirshahi M., Irache J.M. Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography. J Chromatogr A 2000, 870:159-167.
19. Xu K., Lanuti M., Lambright E.S., Force S.D., Albelda S.M., Blair I.A. A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry. Biomed Chromatogr 2000, 14:93-98.
20. Singh O., Saxena S., Mishra S., Khuroo A., Monif T. Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. Clin Biochem 2011, 44:907-915.
21. Xu H.R., Li X.N., Chen W.L., Liu G.Y., Chu N.N., Yu C. A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848:329-334.
22. Heinig K., Wirz T., Gajate-Perez A., Belli S. Determination of ganciclovir and its prodrug valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:436-442.
23. Churchwell M.I., Twaddle N.C., Meeker L.R., Doerge D.R. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J Chromatogr B 2005, 825:134-143.
24. Novakova L., Matysova L., Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006, 68:908-918.
25. Leandro C.C., Hancock P., Fussell R.J., Keely B.J. Comparison of ultraperformance liquid chromatography and high-performance liquid chromatography for the determination of priority pesticides in baby foods by tandem quadrupole mass spectrometry. J Chromatogr A 2006, 1103:94-101.
26. Van De Steene J.C., Lambert W.E. Comparison of matrix effects in HPLC-MS/MS and UPLC-MS/MS analysis of nine basic pharmaceuticals in surface waters. J Am Soc Mass Spectrom 2008, 19:713-718.
27. Chambers E., Wagrowski-Diehl D.M., Lu Z., Mazzeo J.R. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B 2007, 852:22-34.
28. European Medicines Agency Guideline on validation of bioanalytical methods; 2009, London Available at:, [Accessed: 22 April 2012]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
29. Clinical and Laboratory Standards Institute, International Federation of Clinical Chemistry and Laboratory Medicine Mass spectrometry in the clinical laboratory: general principles and guidance. C50-P 2007, CLSI, Wayne, PA.
30. Clinical and Laboratory Standard Institute Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. EP6-A 2003, CLSI, Wayne, PA.
31. Viswanathan C.T., Bansal S., Booth B., et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 2007, 24:1962-1973.
32. Passing H., Bablok W.A. New biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983, 21:709-720.
33. Passing H., Bablok W.A. General regression procedure for method transformation. J Clin Chem Clin Biochem 1988, 26:783-790.
34. Altman D.G., Bland J.M. Measurement in medicine: the analysis of method comparison studies. Statistician 1983, 32:307-317.
35. Bland J.M., Altman Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 327:307-310.